BMY Cash & equivalents
Cash & equivalents at Bristol Myers Squibb fell to $10.2B in fiscal 2025, from $10.3B in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 14272 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$10.2B
FY2024 $10.3B
HIGH$14.0B FY2021
LOW$9.1B FY2022
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $10.2B | $-137M |
| FY2024 | $10.3B | $-1.1B |
| FY2023 | $11.5B | +$2.3B |
| FY2022 | $9.1B | $-4.9B |
| FY2021 | $14.0B | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · BMY company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.